Viking Therapeutics to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Viking Therapeutics (NASDAQ: VKTX) announced participation at two investor conferences in Miami the week of March 8–11, 2026. Management will hold a fireside chat on March 10, 2026 at 10:40–11:10 a.m. ET at the Leerink Partners Global Healthcare Conference and conduct 1-on-1 investor meetings at Leerink and the Jefferies Biotech on the Beach Summit (March 10–11).
A live webcast of the Leerink fireside chat will be available via the company's Investors & Media — Webcasts page, with a replay posted on the website after the conference.
Positive
- None.
Negative
- None.
News Market Reaction – VKTX
On the day this news was published, VKTX gained 4.67%, reflecting a moderate positive market reaction. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $171M to the company's valuation, bringing the market cap to $3.83B at that time.
Data tracked by StockTitan Argus on the day of publication.
Details of the company's participation are as follows:
- Leerink Partners Global Healthcare Conference 2026
Details: Viking management will participate in a fireside chat and in 1-on-1 meetings
Conference Date: March 8-11, 2026
Fireside Chat Timing: 10:40 – 11:10 a.m. Eastern on Tuesday, March 10, 2026
Location:Miami, FL
- 2026 Jefferies Biotech on the Beach Summit
Details: Viking management will participate in 1-on-1 meetings
Conference Dates: March 10-11, 2026
Location:Miami, FL
A live webcast of the Leerink presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302705936.html
SOURCE Viking Therapeutics, Inc.
FAQ
When will Viking Therapeutics (VKTX) hold its Leerink fireside chat at the 2026 conference?
How can investors watch the VKTX Leerink presentation live or on replay?
Which investor conferences will Viking Therapeutics (VKTX) attend March 8–11, 2026?
Will a replay of the VKTX Leerink fireside chat be available after the event?
